ImmuCell Corporation ( ICCC) Stock. Should you Buy or Sell? $ 7.76
-0.09 (-1.17 %)
ImmuCell Corporation Analysis
Updated on 10-09-2022| Symbol | ICCC |
| Price | $7.76 |
| Beta | 0.584 |
| Volume Avg. | $9.27 thousand |
| Market Cap | $60.12 M |
| 52 Week Range | $6.96 - $10.96 |
ImmuCell Corporation opened the day at $7.76 which is -1.17 % on yesterday's close. ImmuCell Corporation has a 52 week high of $10.96 and 52 week low of $6.96, which is a difference of $4. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $60.12 M and total net profit is $19243000 which means the company is trading at 3.12 times profit to market capitalization. Theoretically, if you were to buy ImmuCell Corporation for $60.12 M, it would take 15 years to get your money back. ImmuCell Corporation are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.
Price Chart
Financials
ImmuCell Corporation Stock Forecast - Is ImmuCell Corporation a Buy or Sell?
| DCF Score | Strong Buy | |
| ROE Score | Neutral | |
| ROA Score | Neutral | |
| DE Score | Neutral | |
| PE Score | Strong Sell | |
| PB Score | Strong Buy | |
| Overall Recommendation | Buy |
Growth and Value
| PE Ratio | 194.000 |
| Dividend Yiel | 0.000 |
| Net Profit Margin | 0.013 |
Valuing ImmuCell Corporation
| Price Book Value Ratio | 1.834 | Price To Book Ratio | 1.834 |
| Price To Sales Ratio | 2.938 | Price Earnings Ratio | 219.380 |
How liquid is ImmuCell Corporation
| Current Ratio | 6.907 |
| Quick Ratio | 4.975 |
Debt
| Debt Ratio | 0.287 | Debt Equity Ratio | 0.403 |
| Long Term Debt To Capitalization | 0.246 | Total Debt To Capitalization | 0.264 |
Latest news about ImmuCell Corporation
ImmuCell Corporation (NASDAQ:ICCC ) Q2 2022 Earnings Conference Call August 12, 2022 9:00 AM ET Company Participants Joe Diaz - Investor Relations Michael Brigham - President and Chief Executive Officer Conference Call Participants George Melas - MKH Management Operator Good morning. This is Anthony from Chorus Call and I will be assisting with our conference call this morning.
Conference Call Scheduled for Friday, August 12, 2022 at 9:00 AM ET Conference Call Scheduled for Friday, August 12, 2022 at 9:00 AM ET
ImmuCell Corporation (NASDAQ:ICCC ) Q1 2022 Earnings Conference Call May 13, 2022 9:00 AM ET Company Participants Joe Diaz - Lytham Partners, IR Michael Brigham - President and CEO Joseph Crabb - Former Chief Scientific Officer and VP Operator Good morning. This is Andrea from Chorus Call.
Conference Call Scheduled for Friday, May 13, 2022 at 9:00 AM ET Conference Call Scheduled for Friday, May 13, 2022 at 9:00 AM ET
ImmuCell Corp (ICCC) CEO Michael Brigham Q4 2021 Results Earnings Call Transcript
About ImmuCell Corporation
Description :
ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.
